Table 1

Percentage of patients experiencing adverse events at 90 days in the randomised clinical trials

TreatmentControl
Death0.80.6
COPD exacerbation with hospitalisation9.24.8
COPD exacerbation without hospitalisation10.515.7
Infection1.20
Respiratory failure2.20.7
Pneumonia distal to valve1.9–
Pneumonia other lobe2.82.0
Haemoptysis: massive0.60
Pneumothorax: >7 days2.20
Emphysema00

  • Data derived from Sciurba et al24 Herth et al25 and Ninane et al.26

  • COPD, chronic obstructive pulmonary disease.